| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/26/2008 | US7335680 Preterm labor, dysmenorrhea, asthma, hypertension, fertility disorder, sexual dysfunction, undesired blood clotting, bone disorders, preeclampsia or eclampsia, or an eosinophil disorder; use with phosphodiesterase inhibitors; e.g. 7-[(2R,3R)-3-Chloro-1-(4-hydroxynonyl)-pyrrolidin-2-yl]-hept-5-enoic acid |
| 02/26/2008 | US7335679 Wortmannin analogs and methods of using same |
| 02/26/2008 | US7335678 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor |
| 02/26/2008 | US7335677 Inhibitors of dipeptidyl peptidase IV |
| 02/26/2008 | US7335676 Methods for treating inflammatory conditions or inhibiting JNK |
| 02/26/2008 | US7335674 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof |
| 02/26/2008 | US7335673 2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage |
| 02/26/2008 | US7335672 Vanilloid receptor ligands and their use in treatments |
| 02/26/2008 | US7335671 containing a 2-(hetero)aryloxazol-4-ylalkylcycloalkyl group, (2R/2S)-3-[(1R,3S)-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxymethyl)-cyclohexyloxy ]-2-(4-trifluoromethylbenzyloxy)propionic acid; treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization and insulin resistance; |
| 02/26/2008 | US7335670 Specific inhibitors of the glycine transporters glyt1 and/or glyt2; psychoses, contracture, pain, Parkinson's disease, epilepsy, and sleep apnea |
| 02/26/2008 | US7335669 Use of dihydroquinoline to aid in increasing milk production and feed utilization |
| 02/26/2008 | US7335668 Gastrointestinal disorders; urogenital disorders |
| 02/26/2008 | US7335667 Use as anticancer agents, immunosuppressants for transplants or autoimmune diseases, or against immune reactions (e.g. contact dermatitis or diarrhea) caused by other drugs; e.g. 3-(3-[methyl(1H-pyrrolo[2,3-b]pyridin-4-yl)amino]piperidin-1-yl)-3-oxopropanenitrile |
| 02/26/2008 | US7335666 That inhibit serotonin reuptake and are antagonists of the 5HT1A receptor; 2-[3-(6-Fluoro-indol-1-ylmethyl)-azetidin-1-ylmethyl]-8-methyl-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline for example |
| 02/26/2008 | US7335665 Spirocyclic piperidines as MCH1 antagonists and uses thereof |
| 02/26/2008 | US7335664 Ingesting bisacodyl, metoclopramide, phosphorus compound and sodium; kits |
| 02/26/2008 | US7335663 Heteroaryl compounds which inhibit leukocyte adhesion mediated by α4 integrins |
| 02/26/2008 | US7335662 Such as aurora-2 kinase or c-kit kinase; anticancer agents; based on benzo(4,5)furo(3,2-d)pyrimidine, 9-thia-1,5,7-triazafluorene, or pyrimido(5,4-b)indole rings; e.g. 4-(4-pyrimid-2-ylaminosulfonyl-1,4-phenylene-aminothiocarbonyl)-piperazin-1-yl)-5H-Pyrimido(5,4-b)indole |
| 02/26/2008 | US7335660 Using a 2-benzopyran-6-carboxamide compound |
| 02/26/2008 | US7335659 Substituted 10-aryl-11H-benzo[b]fluorenes and 7-aryl-5, 6-dihydro-benzo[a]anthracenes for selective effects on estrogen receptors |
| 02/26/2008 | US7335658 Pyridazine derivatives and their use as therapeutic agents |
| 02/26/2008 | US7335657 Cytokine inhibitors |
| 02/26/2008 | US7335656 Medical devices employing triazine compounds and compositions thereof |
| 02/26/2008 | US7335655 Treating asthma with e.g. 2-(3-methoxyphenyl)-N-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,9-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yl]acetamide; potent, yet selective modulators of adenosine receptors |
| 02/26/2008 | US7335654 Phosphodiesterase 4 inhibitors |
| 02/26/2008 | US7335653 Bis-aryl sulfonamides |
| 02/26/2008 | US7335652 Introducing into the subject a ligand capable of labelling aggregated paired helical filament (PHF) tau protein, determining the presence and\or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain, correlating the result of the determination |
| 02/26/2008 | US7335651 Controlling concentration of cholesterol, leptin, and serotonine in blood; dietetics; adjust fat oxidation |
| 02/26/2008 | US7335650 Composition |
| 02/26/2008 | US7335649 3-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxy-3'-(tetrazol-5-yl)biphenyl for treatment of thrombocytopenia; colony stimulating factors |
| 02/26/2008 | US7335648 Thrombosis; anticoagulants; renal dialysis |
| 02/26/2008 | US7335647 Drugs for liver diseases |
| 02/26/2008 | US7335646 Compositions and methods for regulated protein expression in gut |
| 02/26/2008 | US7335645 For prophylaxis or treatment of skin or mucosa, autoimmune diseases and inflammation |
| 02/26/2008 | US7335635 14-3-3 binding molecules as sensitizers for anticancer therapies |
| 02/26/2008 | US7335627 Polymeric alkylpolyglycoside carboxylates |
| 02/26/2008 | US7335509 Drug/lipid/polycation complexes; gene therapy |
| 02/26/2008 | US7335505 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 02/26/2008 | US7335482 Method using neutral amino acid transporter expressing cell |
| 02/26/2008 | US7335481 Drug screening for antidiabetic agents, antiobesity agents, treating atherosclerosis; a kits for detection |
| 02/26/2008 | US7335474 Methods and systems for identifying predisposition to the placebo effect |
| 02/26/2008 | US7335389 Beverages containing plant sterols |
| 02/26/2008 | US7335384 Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith |
| 02/26/2008 | US7335380 Tablet, without excessive stickiness or tablet punch residue |
| 02/26/2008 | US7335376 Method for photodynamic therapy and applicator for carrying out said therapy |
| 02/26/2008 | US7335373 N-bromo- or chloro-substituted 7,7,9,9-tetramethyl-1,3,8-triazaspiro[4.5]decane-2,4-dione and 3-(3-trialkoxysilylpropyl) derivatives thereof; surface treatment to render antimicrobial |
| 02/26/2008 | US7335372 Hair wax products containing polyethylene glycol waxes and hydrophobic materials |
| 02/26/2008 | US7335371 Combinations for the treatment of inflammatory disorders |
| 02/26/2008 | US7335362 Methods of treating pre-eclampsia or eclampsia |
| 02/26/2008 | US7335355 Antimicrobial agent |
| 02/26/2008 | US7335353 Porcine cells comprising an adenovirus E3 gene region |
| 02/26/2008 | CA2463001C Solution based methacholine formulations |
| 02/26/2008 | CA2430592C New pharmaceutical compositions based on anticholinergics and dopamine agonists |
| 02/26/2008 | CA2382292C Ibuprofen-containing softgels |
| 02/26/2008 | CA2363124C Use of aromatic polycyclic compounds as activators of ppars-type receptors in a cosmetic or pharmaceutical composition |
| 02/26/2008 | CA2353788C Human cervical cancer 1 protooncogene and protein encoded therein |
| 02/26/2008 | CA2322195C Novel diphenyl-substituted 5-ring-heterocycles, method for producing them and their use as medicaments |
| 02/26/2008 | CA2317044C Medicament for neurodegenerative diseases |
| 02/26/2008 | CA2300910C Phosphono-carboxylate compounds for treating amyloidosis |
| 02/26/2008 | CA2291094C 2-oxoimidazole derivative |
| 02/26/2008 | CA2284142C Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
| 02/26/2008 | CA2238553C Cholesterol-lowering composition |
| 02/26/2008 | CA2230159C Use of aminoadamantane compounds as immunoregulators |
| 02/26/2008 | CA2225813C Antiparasitic marcfortines and paraherquamides |
| 02/26/2008 | CA2207545C Antiarrhythmic (s)-enantiomers of methanesulfonamides |
| 02/26/2008 | CA2200761C Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound |
| 02/24/2008 | CA2558043A1 Methods of correcting bone mineralization defects, kits therefor and compositions therefor |
| 02/21/2008 | WO2008022286A2 Small molecule inhibitors of kynurenine-3-monooxygenase |
| 02/21/2008 | WO2008022267A2 Combination treatment for metabolic disorders |
| 02/21/2008 | WO2008022256A2 Methods and compositions for preventing or treating age-related diseases |
| 02/21/2008 | WO2008022242A2 Synthesis of propyl phenoxy ethers and use as delivery agents |
| 02/21/2008 | WO2008022204A2 Thiourea compounds |
| 02/21/2008 | WO2008022199A2 Apparatus and process for manufacturing food products with omega-3 polyunsaturated fatty acids |
| 02/21/2008 | WO2008022189A2 Administration of high potency platinum compound formulations by inhalation |
| 02/21/2008 | WO2008022182A1 Methods for promoting coupling between bone formation and resorption |
| 02/21/2008 | WO2008022171A1 Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors |
| 02/21/2008 | WO2008022152A2 Optimized antibodies that target cd19 |
| 02/21/2008 | WO2008022128A2 Transdermal delivery of meptazinol |
| 02/21/2008 | WO2008022038A1 Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure |
| 02/21/2008 | WO2008022033A2 Methods for preventing or treating cardiovascular disease |
| 02/21/2008 | WO2008022032A2 Topical pharmaceutical compositions comprising calcium-channel blocker and method of using same |
| 02/21/2008 | WO2008022013A1 Kinase inhibitors |
| 02/21/2008 | WO2008022002A2 2-amido-4-isoxazolyl thiazole compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| 02/21/2008 | WO2008021996A2 Nutritional supplement for increased energy and stamina |
| 02/21/2008 | WO2008021970A2 Treatment of motor neuron disease, including certain neurological disorders, motor neuropathies and chronic inflammatory diseases |
| 02/21/2008 | WO2008021956A2 Acylaminoheteroaryl hepatitis c virus protease inhibitors |
| 02/21/2008 | WO2008021936A2 Hepatitis c virus inhibitors |
| 02/21/2008 | WO2008021933A2 N-aryl or n-heteroaryl pyrazolidine and pyrazolidinone derivatives as prostaglandine receptor inhibitors |
| 02/21/2008 | WO2008021932A2 Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia |
| 02/21/2008 | WO2008021928A2 Hepatitis c virus inhibitors |
| 02/21/2008 | WO2008021927A2 Hepatitis c virus inhibitors |
| 02/21/2008 | WO2008021924A1 Pyrrolotriazine kinase inhibitors |
| 02/21/2008 | WO2008021908A2 Multistage delivery of active agents |
| 02/21/2008 | WO2008021891A2 Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects |
| 02/21/2008 | WO2008021871A2 Triazolyl acyclic hepatitis c serine protease inhibitors |
| 02/21/2008 | WO2008021847A2 Topical formulation of multilamellar vesicles composition for percutaneous absorption of pharmaceutically active agent |
| 02/21/2008 | WO2008021829A2 Topical ceramide compositions and methos of use |
| 02/21/2008 | WO2008021804A2 Therapeutic amides and related compounds |
| 02/21/2008 | WO2008021796A2 Pyrrolidinone anilines as progesterone receptor modulators |
| 02/21/2008 | WO2008021788A2 Polyamine compounds |